A total of 68 Private Equity/Venture Financing deals (pending and completed) were announced in the Pharmaceuticals of United Kingdom, in the last twelve months resulting in a total deal value of over $2,808.7 million. In the LTM period, February 2022 turned out to be the most prolific in terms of deal size, with a total deal value of $625.5 million, resulting in an average deal value of $69.5 million during that month. On the other hand, the month of February 2022 was the most prolific in terms of deal volume, recording a total of 9 deals, resulting in an average deal value of $69.5 million during that month.
Of the 68 deals, the deal secured between Epidarex Capital III UK; Scottish Enterprise and Kynos Therapeutics Ltd, was the largest Private Equity/Venture Financing deal in the United Kingdom Pharmaceuticals sector, which was valued at $506.6 million and was completed on February 3, 2022. The second-largest deal was between Blackstone Life Sciences Advisors LLC and Autolus Therapeutics Plc, while the third-largest deal was between CDC Group Plc.; Development Partners International LLP and KELIX bio. The Blackstone Life Sciences Advisors LLC-Autolus Therapeutics Plc deal and the CDC Group Plc.; Development Partners International LLP-KELIX bio deal were valued at $250.0 million and $200.0 million, respectively. The fourth-largest deal was between British Patient Capital Ltd; Fidelity Management & Research Company; Janus Henderson Investors; Jeito Capital; Monashee Investment Management, LLC; Point72, L.P.; Ridgeback Capital Investments L.P.; SV Health Investors LLP; Syncona Ltd; Tekla Capital Management LLC-Quell Therapeutics Ltd valued at $156.0 million, whereas the deal between Andera Partners; Arix Bioscience Plc; Avidity Partners LLC; CaaS Capital Management; Deep Track Capital LP; Invus Group LLC; IP Group Plc; Life Sciences Partners BV; M Ventures; Novartis Venture Fund; Omega Fund Management LLC; Pfizer Venture Investments; Piper Heartland Healthcare Capital, LLC; RTW Investments LP; Schroders Plc; Sofinnova Partners SAS; Soleus Capital Management LP; SV Health Investors LLP; TCG Crossover; Tetragon Financial Group Ltd-Artios Pharma Ltd valued at $153.0 million was the fifth-largest deal.
Cumulatively, the top five deals amounted to $1,265.6 million and accounted for nearly 45.06% of the total deals (by value) announced during the last twelve months.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
United Kingdom
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward